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1. Introduction  
Since the first percutaneous transluminal coronary angioplasty (PTCA) performed by 
Andreas Gruntzig in 1977 the technology has evolved significantly. Progress of PTCA has 
seen the development of many devices, some of which are still in use and many others that 
have fallen in disuse. The main limitation of the plain old balloon angioplasty (POBA) was 
the problem of elastic vascular recoil causing abrupt vessel closure and restenosis. The 
patho-mechanism of restenosis that occurs following balloon angioplasty involves negative 
vascular remodeling, elastic recoil and thrombosis at the site of injury {Moreno, 1999}. While 
the thrombus formation can be reduced by use of antiplatelet drugs, the restenosis threat 
remains. Early restenosis occurred in as many as 30% of angioplasty cases. This led to the 
development of the metal stent to exert radial force on the vessel wall and thus prevent 
elastic recoil. Although stents reduced restenosis, their use led to the realisation of a 
different and new challenge of in stent restenois (ISR). This occurs mainly due to neointima 
formation {Mach, 2000,Mudra et al, 1997, Hoffman et al, 1996, Kearney et al, 1997} that is 
principally composed of proliferating smooth muscle cells (SMC) and extra cellular matrix 
{Geary et al, 2003, Grewe et al, 1999}. By the late 1990s, it was acknowledged that although 
the incidence of ISR was lower than that of restenosis following balloon angioplasty 
{Serruys et al, 1991}, it occurred in 15–30% of patients, and possibly more frequently in 
certain subgroups {Holmes et al, 2002}. 
2. Treatment of restenosis 
Over the years there have been intensive research efforts to identify possible 
pharmacotherapeutic regimens to prevent the neointimal restenotic process. Although most 
experimental studies and some small initial clinical studies showed promise, subsequent 
large randomized trials have been disappointing {Faxon, 1995, Bertrand et al, 1997, Boccuzzi 
et al, 1998, Serruys et al, 2000, Faxon, 2002}. Failure to achieve significant reduction in ISR 
with systemic drug therapy led to the exploration of the concept of local drug delivery. 
Local drug delivery (LDD), in theory, should achieve greater local drug concentration with 
lower overall dose compared to systemic therapy, to help achieve maximal tissue effects 
while minimizing undesired systemic toxicity. It also has the advantage of being able to 
utilize drugs with low systemic bioavailability or short half-life. Many devices have been 
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developed to administer drugs or genetic material locally to the site of injury {Sharma et al, 
2011}. Studies have shown that local administration of pharmacologic agents directly at the 
site of coronary intervention is an effective means of delivering sufficient amount of drug 
into the injured arterial tissue site to cause an anti-restenotic therapeutic effect { Schwartz et 
al, 2004}.  
Various approaches for local drug delivery have been tried including nanoparticles, contrast 
media and drug delivery balloons, such as porous {Herdeg et al, 2000} and double balloons 
{Oberhoff  et al, 2001}. Other options for treating ISR included POBA using either 
conventional or cutting balloons, implanting a stent inside the stent, rotablation or 
brachytherapy.  However, most of these techniques were not adopted into widespread 
clinical use due to their various shortcomings and limitations. Until recently, stent-based 
local drug delivery using drug-eluting stents (DES) is still considered the percutaneous 
treatment of choice for coronary restenosis. As the process of neo intimal hyperplasia occurs 
locally due to endothelial injury caused by the metallic stent, it seems logical to use the stent 
itself to deliver a drug locally in order to overcome this problem. 
Thus DES have become the mainstay of intervention for coronary atherosclerotic disease 
{Kirtane et al, 2009}. However, DES use is limited by small but unpredictable risk of late 
stent thrombosis due to withdrawal of antiplatelet therapy { McFadden et al, 2004}, delayed 
mal-apposition {Kozuma et al, 1999}, delayed vascular healing as a result of initial anti-
proliferative effect {Jakabcin et al, 2008}, or a hypersensitivity reaction to the drug, polymer 
coating or both { Finn et al, 2007}.  
ISR continues to occur with DES, although at a lower rate compared to BMS. However, the 
relative massive increase in number of DES implantations in recent years means the 
problem of ISR although less in relative terms compared to BMS, still causes a problem in 
absolute terms requiring a significant number of repeat procedures every year globally and 
remains a treatment challenge {Maisel, 2007}. Treatment of restenosed DES with a second 
DES is associated with risk of subsequent restenosis of up to 43% {Lemos et al, 2008}. The 
ideal treatment of a coronary stenosis would eliminate both the stent and the polymer 
related late problems, while at the same time deliver an antiproliferative agent to reduce the 
risk of restenosis. 
3. Drug eluting balloons 
Old-style balloon angioplasty married to the latest in drug-eluting technology, resulting in a 
drug eluting balloon (DEB), may be an effective alternative to stenting, in particular to 
overcome the problems of restenosis and ISR. Such a device would potentially overcome the 
drawbacks of stenting, polymer-related delayed endothelialization, and stent delivery, while 
at the same time providing homogenous drug delivery to the vessel wall, allowing earlier 
endothelialization and flexibility of use in complex lesions. However, its limitations include 
the failure to provide a mechanical scaffold for the prevention of acute recoil and the 
problem of not being able to treat dissection flaps. 
Drug eluting balloons achieve LDD by means of an angioplasty balloon coated with drugs 
such as paclitaxel, which are well established in DES technology. One of the commercially 
approved devices, the SeQuent® Please (Braun, Germany) balloon catheter (Fig. 1) has a 
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folded balloon, which is homogenously coated with paclitaxel embedded in contrast 
medium coating. Paclitaxel (3 μg/ 373mm2 balloon surface) is the pharmacologically active 
substance whereas the contrast medium has a matrix builder function to facilitate 
immediate release of drug during balloon inflation {Scheller & Speck, 2009}.  
 
Fig. 1. Photograph of SeQuent (top) and the paclitaxel coated SeQuent® Please balloon 
catheter (bottom). 
The ideal drugs for local delivery should be lipophilic in nature, rapidly adsorbed and have 
a high retention rate by the vessel intima, in order to exert maximal beneficial effects 
{Baumbach et al, 1999}. Paclitaxel is a lipophilic drug and bind tightly to various cell 
constituents {Rowinsky et al, 1995}, resulting in effective local retention at the site of 
delivery { Creel et al , 2000} and it exerts a long-lasting effect in the cell due to structural 
alteration of the cytoskeleton. Thus, paclitaxel, with its lipophilic nature, combined with 
the fact that adding a small amount of hydrophilic contrast medium {Scheller et al, 2003} 
enhances its solubility, makes it well suited for delivery on a drug-delivery balloon. 
Various other drugs like, sirolimus, zotarolimus, rapalog and others are being studied 
currently as a possible alternative to paclitaxel for coating the PTCA balloon {Schnorr et 
al, 2010}. 
3.1 Pre- clinical data 
The first preclinical study was conducted by Scheller et al {Scheller et al, 2004}. In this study 
stainless steel stents (n = 40; diameter: 3.0–3.5 mm; length: 18 mm) were implanted in the left 
anterior descending and circumflex coronary arteries of pigs. Both conventional uncoated 
and three different types of paclitaxel-coated coronary angioplasty balloons were used, and 
contact with vessel wall was maintained for 1 min. The results were assessed by quantitative 
angiography and histomorphometric studies of the stented arteries. There was a marked 
reduction (up to 63%) of parameters characterizing ISR in the paclitaxel-coated balloon 
group, without evidence of increased inflammation in proximity to the stent struts or any 
effect on re-endothelialisation of the struts. They also showed that paclitaxel-coated balloons 
lose only 6% of the drug when introduced into the coronary circulation and retracted 
without inflation. Approximately 80% of the drug is released during inflation, suggesting 
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rapid transfer of the drug from the balloon to the vessel wall without much loss. In this 
study, the percentage of drug recovered from the vessel wall was at a maximum (17.3%) 
when a premounted stent on a coated balloon was used, compared with postdilatation using 
a coated balloon (15.6%) or the coated balloon on its own (8.7%). 
Speck and colleagues compared non-stent-based drug delivery with DES in reducing 
neointimal proliferation in a porcine model. The study group was divided into four groups 
as follows; Group A was the control group with uncoated balloons, BMS and ‘plain’ contrast 
medium. Group B was the same treatment as A, but with paclitaxel in the contrast medium. 
Group C was paclitaxel-coated balloons, with pre-mounted BMS and plain contrast 
medium. Finally, group D was sirolimus-eluting stents, non-coated balloons, and plain 
contrast medium. At 4 weeks, assessment of stenosis was carried out using angiography and 
histomorphometry. The most impressive inhibition of neointimal proliferation was achieved 
in the coated balloon group – the neointimal area was 2.4 mm2 ± 0.3 (p < 0.01 vs. all other 
groups), compared with 5.2 mm2 ± 0.3 in group A, 4.3 mm2 ± 0.3 in group B, and 3.8 mm2 ± 
0.3 in group D {Speck et al, 2006}. 
Cremers and colleagues studied the relationship between the inflation time and dose of 
placlitaxel on the DEB, on effectiveness in reducing neo-intimal proliferation in a porcine 
model {Cremers et al, 2009 a}. DEB technology was shown to be effective in reducing 
neointimal proliferation regardless of the balloon inflation time (10 s, 60 s and two 60 s 
inflations) and dose (up to a total amount of 10 μg paclitaxel/mm² balloon surface). This 
study showed that drug transfer occurs very early after balloon inflation and also 
demonstrated the safety profile of applying several balloon inflations within the same vessel 
either using the same or additional balloons.  
In a comparative study of two different types of DEB (Original Paccocath-coating, similar to 
SeQuent®Please, B. Braun, Germany and DIOR®, Eurocor, Germany) on a porcine coronary 
overstretch model it was demonstrated that much better results were obtained with the 
matrix-coated Paccocath DEB compared with the roughened surface DIOR balloon, 
suggesting that inhibition of neointimal proliferation is dependent on the coating method 
used {Cremers et al, 2009 b}. In a comparative DEB performance study by Joner et al, in a 
porcine model of advanced coronary restenosis, significant heterogeneity of neointimal 
suppression was seen between the devices tested {Joner et al, 2011} 
3.2 Use of DEB in the human coronary 
The first reports of DEB use in humans were the Paccocath ISR I and ISR II studies in 2006. 
These were randomized, double-blind German multicenter clinical trials to assess the 
efficacy and tolerability of a paclitaxel-coated balloon catheter in the treatment of coronary 
ISR {Scheller et al, 2006, 2008}. Scheller and colleagues enrolled 108 patients (52 and 56 
patients in each study) with a single ISR lesion to undergo balloon angioplasty either using a 
3mcg/mm2 iopromide-paclitaxel coated balloon (PACCOCATH, Bayer Schering Pharma) or 
a standard uncoated balloon of the same type. The primary end point of angiographic in-
segment late lumen loss was markedly different in the two groups. They reported that at 6-
month follow-up, in-segment late lumen loss was 0.81 ± 0.79 mm in the uncoated balloon 
group, versus 0.11 ± 0.45 mm (p < 0.001) in the drug-coated balloon group. By 12 months, 
only two patients in the coated balloon group required target vessel re-vascularization (p = 
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0.001), compared with 20 in the control group. A sustained clinical effect of the DEB was 
noted at 24 months with no subacute thrombosis or other safety concerns. 
The Paclitaxel-Eluting PTCA-balloon catheter in Coronary Artery Disease (PEPCAD I-SVD) 
was a Phase II nonrandomized, open label, uncontrolled, efficacy study evaluating the use 
of a DEB catheter (SeQuent Please, B. Braun, Germany) for the treatment of small vessel 
coronary artery disease in 118 patients (reference diameter of 2.25–2.8 mm and lesion length 
≤ 22 mm). If the angiographic result was not satisfactory at the end of the procedure, the 
subjects could be treated with any device, but a bare metal stent was recommended. After 6 
months, de novo lesions treated solely with DEB or in combination with BMS (28% of 
patients) showed a 17.3% binary restenosis rate, and at 1 year 11.7% target lesion 
revascularization (TLR) and 15% major adverse cardiovascular event rate {Scheller, 2008}. 
However, in the patients who received DEB alone (n = 82) without additional stent 
insertion, the binary restenosis rate was only 5.5%. The somewhat higher restenosis rate in 
the total population may have been attributable to ‘geographic mismatch’ between the DEB-
treated area and the subsequently stented surface area. 
The PEPCAD II-ISR trial was a prospective, randomized study directly comparing the 
paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun, Germany) to the paclitaxel-
eluting stent (Taxus®, Boston Scientific, MA, USA) in 131 patients with ISR, followed up for 
6 months. The main inclusion criteria encompassed diameter stenosis of ≥70% and ≤22 mm 
in length, with a vessel diameter of 2.5 to 3.5 mm. In 6.2% of the Taxus stent group, the stent 
was undeliverable and a balloon catheter had to be used instead. Clopidogrel was given for 
3 months post treatment to the balloon group and 6 months to the stent group. Patients 
treated with the drug-eluting balloon experienced a 7.0% ISR compared with 20.3% in the 
group. Adverse cardiac events occurred in 22% of the stent group and in 9% of the coated 
balloon group (p = 0.08), driven predominantly by reduced need for target lesion 
revascularisation (TLR), which was 6.3 and 15.4% in the balloon and stent groups, 
respectively {Unverdorben et al, 2009}. These findings suggested that DEB is at least as 
efficacious and as well tolerated as DES in treating ISR. 
PEPCAD III  {Hamm, 2009} was a prospective, randomised, multi-centre, Phase II pilot 
study which compared the combination of paclitaxel-coated DEB plus BMS (Coroflex® 
DEBlue, B. Braun) with the sirolimus eluting CYPHER® stent in the treatment of de novo 
native coronary stenoses with stent diameters between 2.5 and 3.5 mm and less than 24 mm 
in length. The primary end point was late lumen loss in treated segment at 9 months 
assessed angiographically. The 637 patients with stable or unstable angina or documented 
ischemia (ST-elevation myocardial infarction and non-ST-elevation myocardial infarction 
excluded) were randomized to undergo PCI with either the paclitaxel DEB plus BMS (n = 
312) or the sirolimus DES (n = 325). The in-stent late lumen loss was 0.41 ± 0.51 mm in the 
DEB + BMS group compared with 0.16 ± 0.39 mm in the DES group (p < 0.001). In segment 
late lumen loss in the two groups were 0.20 ± 0.52 mm and 0.11 ± 0.40 mm (p = 0.06), 
respectively. Target-vessel revascularization (13.8 vs. 6.9%, p < 0.01) and TLR (10.5 vs. 4.7%, 
p < 0.01) rates were also significantly higher in the DEB + BMS subgroup at 9 months. Of the 
safety end points, the rate of myocardial infarction at 9 months was 4.6 and 0.3% (p < 0.001) 
in the DEB plus BMS and DES groups, respectively. In addition, stent thrombosis by 
Academic Research Consortium criteria was 2.0 and 0.3%, respectively (p < 0.05). These 
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results show that the drug-eluting balloon-stent system did not meet the non-inferiority 
criteria versus the CYPHER stent and the safety aspects need further investigation  
In a study of 20 patients, in the Drug-Eluting Balloon In Bifurcation Utrecht [DEBIUT] 
registry {Fanggiday et al, 2008}, Fanggiday assessed the efficacy and safety of different type 
of DEB in treating bifurcation lesions. The bifurcation lesions (main and side branch) were 
treated with the paclitaxel-coated DIOR balloon followed by BMS implantation only in the 
main branch. At 4-months follow-up, no major acute coronary events and no subacute 
vessel closure were reported. There was no angiographic follow-up performed in this 
study, making it difficult to assess the results, although the fact that major adverse 
cardiovascular event rates were not elevated after 4 months indicates that the coating of 
this balloon is well tolerated, but the small number of cases makes this woefully 
underpowered. 
Recently, The PICCOLETO Trial {Cortese et al, 2010} failed to show the ‘non-inferiority’ of a 
paclitaxel-eluting balloon (DIOR, Eurocor, Germany) compared with a paclitaxel eluting 
stent (Taxus Liberte, Boston Scientific, MA, USA) in terms of restenosis for the treatment of 
small coronary arteries (≤2.75 mm). This was a small, single-centre, randomized controlled 
study that intended to randomize eighty patients with stable or unstable angina undergoing 
PCI in small vessels (≤2.75 mm) to receive either a DES (Taxus Liberte) or a DEB (DIOR). 
The enrolment into this study was halted after two thirds of the originally intended number 
of patients because of a marked outcome difference in the two groups. The 6-month 
angiographic follow-up of the 57 patients revealed that the primary end point was not met, 
because the DEB group showed higher per cent diameter stenosis (43.6% vs. 24.3%, 
p=0.029); angiographic restenosis was higher as well (32.1 vs. 10.3%, p=0.043), whereas 
MACE was 35.7% in the PCB group and 13.8% in the DES group (p=0.054).  
The results of the PEPCAD V were presented at the Transcatheter Therapeutics 2009 
{Mathey, 2009}. This was a small feasibility and safety trial using DEBs (SeQuent Please, B. 
Braun) for the treatment of coronary bifurcation disease, specifically by using DEB in main 
and side branches, a BMS in the main branch, and a provisional BMS strategy in the side 
branch. Twenty-eight patients were treated in 2 German centres. Achievement of the 
primary end point (<30% stenosis in the main branch, <50% stenosis in the side branch) at 9 
months follow up occurred in 97% and 89% of vessels, respectively. Although there were no 
deaths during the follow-up, 2 late stent thromboses occurred in the main branch where 
DEB was used with BMS. Thus this small study indicated evidence of efficacy but the 
observed late stent thrombosis raised the issue of safety of DEBs used in combination with 
BMS. 
There are several other studies ongoing, evaluating the role of DEB in treatment of coronary 
artery disease in various clinical settings. Some of them are listed in the table 1.  
4. Limitations of DEB 
Apart from the uncertainty about the choice of drug and the method used to coat the 
balloon there are still many more unanswered questions regarding the use of DEB. There 
have not been many studies to compare the efficacy and safety of different coating methods 
used. There is a potential risk of systemic toxicity with the loss of drug. As the device is 
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meant for single use it may not be very cost-effective in long lesions or other situations 
requiring multiple inflations and with each application the systemic toxicity is potentially 
higher. It definitely lacks the scaffold effect of a stent that is highly desirable in many clinical 
situations such as the treatment of acute vessel dissection and acute vessel recoil. With 
ongoing studies hopefully the device should improve and perhaps overcome some of these 
limitations. 
 
Study Name Brief Description of study Estimated completion 
DEB-AMI Use of DEB in STEMI 2013 
PEPCAD DES  DEB use in DES ISR May 2011  
KISSING DEBBIE Use of kissing DEB in 
Bifurcation lesion 
2011 
PEPCAD-BIF DEB in bifurcation lesions November 2012 
ISAR DESIRE 3  Treatment of ISR with DEB 
vs. DES vs. POBA 
July 2014  
SEDUCE  OCT analysis of DEB vs. DES 
treatment of restenosis 
December 2015  
PEPCAD IV  DEB in native coronary 
stenosis of Diabetic patients 
September 2011  
PEPCAD CTO  DEB in treatment of chronic 
total occlusion 
September 2014  
INDICOR  BMS +DEB post dilatation vs 
DEB predilation + BMS 
implantation 
April 2012  
PEPCAD DEB  DEB vs. DES in De-novo 
coronary stenosis 
March 2015  
WinDEB Study Pressure wire guided DEB vs. 
DES use in SVD 
Not Recruiting yet 
VIBER IVUS assisted DEB use Recruiting 
Table 1. Ongoing trials for DEB use in coronary intervention (Source Clinical Trials.gov) 
5. Summary  
With increasing numbers of coronary revascularisations taking place globally, the 
challenges and late complications of percutaneous intervention are also growing. The search 
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for an ideal device for PTCA is ongoing. The problem of restenosis is very well described as 
the ‘Achilles heel’ of coronary intervention. It not only necessitates repeat procedures but 
also significant symptoms in patients and the treatment is challenging. After the failure of 
systemic pharmacotherapy, local drug delivery at the coronary lesion site is the current 
treatment strategy for restenosis and the stent-based platform is the most extensively used. 
The limitations of DES {Sharma et al, 2010} and problems of late stent thrombosis have 
shifted the treatment goal from procedural success to keeping the long-term problems 
minimal.  
The concept of DEB originated more than a decade ago but only has come into clinical use 
recently. Although it showed some initially promising results in animal study and first in 
man trials, the subsequent studies have failed to demonstrate their superiority over more 
traditional approaches. DEB certainly seems to offer promise in the treatment of ISR, and 
possibly in de novo lesions in small coronary vessels. In such scenarios it has several 
advantages over DES: it helps to avoid the double/triple metal layer which results in 
making the coronary vasculature into a metal jacket, thereby distorting the anatomy; it 
potentially provides homogenous drug distribution in the vessel wall, thus reducing the 
effects of delayed endothelialization of stent struts; it is free of the polymer matrix used in 
DES, thus removing the stimulus for late thrombosis; advantages are observed despite a 
shorter period of dual antiplatelet therapy usage, thus probably reducing costs and 
problems associated with prolonged dual antiplatelet treatment; and may have a role in 
small, tortuous, heavily calcified coronaries or bifurcation lesions, where DES continues to 
underperform.  
The 2010 European Society of Cardiology Myocardial revascularisation guidelines suggest 
considering DEB use in treatment of BMS restenosis and for DEB with proven 
efficacy/safety profile, according to the respective lesion characteristics of the studies {ESC 
& EACTS, 2010}.  Overall the data available so far does not convince us that DEB will 
replace all DES. Further studies are required in selective lesion subtypes. It is definitely a 
promising new treatment strategy on the coronary interventionist’s shelf. 
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